Scope and claims of US Patent 10,183,003: glyceryl tri-[4-phenylbutyrate] dose adjustment for UCD based on a single fasting ammonia test
US Patent 10,183,003 claims a dosing-and-monitoring algorithm for treating urea cycle disorders (UCD) with glyceryl tri-[4-phenylbutyrate] (GT4P, glycerol tri(4-phenylbutyrate)). The method is restricted to patients who are not in hyperammonemic crisis and who have a fasting venous ammonia level below the lab “upper limit of normal” (ULN). The core claim is a single fasting venous ammonia measurement after GT4P steady state, followed by an oral dose adjustment upward only if the fasting ammonia exceeds half the ULN. Dependent claims narrow key parameters: steady-state timing windows, a repeat-evaluate loop, and specific numeric/assay conditions (e.g., 35 μmol/L ULN and overnight fasting).
What does US 10,183,003 cover, and who is eligible under claim 1?
Immediate scope answer (claim 1): The patent covers a method of treating a UCD subject using an initial oral GT4P dose, then after GT4P is at steady state, performing one fasting venous ammonia measurement and adjusting the GT4P dose based on a threshold tied to half the lab ULN.
Eligibility constraints baked into claim 1
Claim 1 requires all of the following:
-
Indication/condition
- “A method of treating a subject with a urea cycle disorder (UCD)…”
-
Exclusion of crisis
- Subject “is not experiencing a hyperammonemic crisis.”
-
Baseline ammonia gate
- Subject has “a fasting venous blood ammonia level less than the upper limit of normal.”
-
Dosing and monitoring steps
- Oral initial dosage of GT4P.
- After a sufficient time period for GT4P to reach steady state:
- Measure a single fasting venous blood ammonia level.
- Compare to lab-specific ULN (explicitly relative to “reference range of normal values at the laboratory in which the ammonia was measured”).
- Oral adjusted dosage of GT4P:
- Adjusted dosage is greater than initial dosage if fasting venous ammonia level is greater than half the ULN.
-
Probability-supported treatment threshold statement
- “wherein a subject with a fasting ammonia in the range 0-0.5 ULN has a greater than 80% likelihood of having an average daily ammonia level within a normal range.”
How the claim operationalizes “lab-specific ULN”
Instead of fixing one ammonia cutoff, claim 1 uses relative ULN defined by the measuring laboratory’s reference range. That matters for:
- claim construction (ULN is not universal; it is assay- and lab-dependent),
- design-around risk (different assay/reference range choices may be argued as changing the “upper limit of normal” used for comparison).
What is “single fasting venous blood ammonia level” enforcing
The claim is explicit that the steady-state assessment is one measurement, not serial draws. That limits direct coverage by:
- protocols using multiple fasting samples at steady state,
- protocols using area-under-curve or serial ammonia profiling.
What is the core dosing algorithm claimed in US 10,183,003?
Step-by-step mapping to claim 1 elements
-
Oral administration: initial GT4P dose
- No numeric initial dose in the claim excerpt you provided, so the breadth is driven by later dependent claims only where you stated timing/numeric thresholds.
-
Steady-state timing occurs before monitoring
- A “time period sufficient for GT4P to reach steady state.”
-
One fasting venous ammonia test
- “measuring a single fasting venous blood ammonia level… not serial blood draws.”
-
Threshold comparison
- Compare measured ammonia to lab ULN.
- Adjust only based on whether measured fasting ammonia is:
- ≤ 0.5 ULN (no upward adjustment implied by claim 1 language),
-
0.5 ULN (upward adjustment required by claim 1).
-
Dose adjustment
- Adjusted dosage is “greater than the initial dosage” if the fasting ammonia is greater than half the ULN.
-
Probability statement
- The method is linked to an evidentiary expectation: patients with fasting ammonia 0 to 0.5 ULN have >80% likelihood of normal average daily ammonia.
Claim-driven interpretation of “adjusted dosage greater than initial dosage”
The wording does not describe a scenario where adjusted dosage is lower or unchanged. Coverage is for methods that:
- perform the specified test after steady state, and
- prescribe an adjusted dose greater than initial when the fasting ammonia exceeds 0.5 ULN.
This can create leverage in litigation for method claims: if a protocol adjusts downward or holds dose constant when >0.5 ULN, the accused method may fall outside.
What do the dependent claims narrow, and how do they change claim breadth?
Dependent claims 2–6: steady-state timing windows
Claim 1 uses a functional standard: “time period sufficient… to reach steady state.” Dependent claims add concrete ranges:
- Claim 2: steady state at 48 hours
- Claim 3: 48 to 72 hours
- Claim 4: 72 hours to 1 week
- Claim 5: 1 week to 2 weeks
- Claim 6: greater than 2 weeks
Practical impact on scope
These dependent claims suggest the specification contemplates steady state across multiple dosing regimens or pharmacokinetic assumptions. From a freedom-to-operate lens, any protocol that matches claim 1 but uses a steady-state interval not captured by the dependent claims may still potentially infringe claim 1 if “sufficient for steady state” is met, but dependent claims strengthen coverage for protocols that choose these explicit windows.
Dependent claim 7: repeat-evaluate loop
- “further comprising repeating steps (b) to (d) until… fasting venous blood ammonia… at or below half the ULN”
This expands coverage to iterative titration protocols. It also distinguishes between:
- single titration (baseline described in claim 1 only), and
- repeated titration until a target is met (claim 7).
Dependent claim 8: specific ULN numeric value
This adds a laboratory-independent numeric anchor. Any accused protocol using a different ULN definition (or converting/using different units) is a direct potential non-infringement angle for claim 8 specifically, but not necessarily for claim 1 since claim 1 is relative to lab ULN.
Dependent claim 9: fasting regimen
- fasting period obtained via “overnight”
This narrows the testing methodology. Protocols specifying a different fasting duration (e.g., 2–4 hours) would avoid claim 9 while still potentially infringing claim 1 if “fasting” is otherwise satisfied and steps align.
How does US 10,183,003 relate to typical GT4P (Buphenyl/phenylbutyrate) UCD management, and what differentiates this patent?
Differentiators emphasized by the claim language
- Dose adjustment criterion based on a single fasting venous ammonia level after steady state.
- Threshold is pegged to the lab ULN and uses half-ULN.
- Explicitly restricts to subjects not in hyperammonemic crisis.
- Probability-linked expectation for patients whose fasting ammonia is between 0 and 0.5 ULN.
Design-around fault lines likely to matter
Because the claim is a method with specific measurement and titration structure, non-infringement arguments typically focus on:
- Measurement structure: using serial ammonia values rather than “a single” value.
- Adjustment rule: using dose reduction or no upward adjustment even when fasting ammonia exceeds half-ULN.
- Population gate: treating crisis patients or starting when fasting ammonia is not below ULN.
- Testing protocol: not using overnight fasting (claim 9), or using a non-venous source (note: claim requires venous).
- ULN definition: using an internal cutoff that is not the lab “upper limit of normal,” or shifting to a protocol that cannot be mapped to the lab reference range ULN concept.
What is the claim “center of gravity” for infringement exposure?
Most commercially relevant reading
The center of gravity is claim 1 because it is:
- the broadest claim you supplied,
- not limited to a single numeric ULN,
- not limited to a specific steady-state range (though dependent claims provide those),
- not limited to overnight fasting.
Where dependent claims matter in practice
- If a GT4P label or protocol specifies overnight fasting and an ULN of 35 μmol/L, claims 8–9 increase coverage certainty.
- If protocols enforce explicit steady-state timing like 48 hours or 48–72 hours, claims 2–3 create tighter correspondence.
What is the likely patent landscape around this claim set (how to position US 10,183,003 in a GT4P/UCD estate)?
Where this patent sits conceptually in GT4P method protection
Based on claim structure, US 10,183,003 is a method-of-treatment / monitoring and dosing adjustment patent, not a compound patent. In a GT4P UCD portfolio, that typically clusters alongside:
- earlier GT4P composition and use patents,
- pharmacokinetic or monitoring frequency patents,
- titration algorithms based on ammonia metrics.
How to think about “coverage density” around method claims
Method portfolios often contain multiple patents with overlapping but distinct claim anchors:
- one patent on dosing initiation,
- one on steady-state timing,
- one on measurement cadence (single vs serial),
- one on threshold levels and lab-specific normalization,
- one on adjustment direction rules.
US 10,183,003 is strongly anchored on the “single fasting measurement after steady state” and “>0.5 ULN triggers dose increase” combination. That combination is a common litigation friction point because it turns on clinical protocol design.
Are there generic or biosimilar risks for US 10,183,003?
Generic entry risk
GT4P is a small molecule. Generic exposure is primarily a function of:
- whether a competitor must practice the claimed method (induced infringement or direct method practice),
- whether clinical guidance and product labels induce the claimed algorithm.
Since this is a method-of-treatment claim, “generic risk” depends on whether the generic’s label or standard of care requires physicians to follow the steps. If the branded sponsor (or label) emphasizes the same algorithm, method enforcement is more plausible.
Biosimilar risk
Not applicable. GT4P is not a biologic.
How to read this patent for licensing and litigation strategy (what you would enforce or challenge)
Enforcement leverage
US 10,183,003 is enforceable against any actor practicing the method:
- clinician instructions,
- protocol-driven use,
- induced method practice tied to product labeling and training.
Key challenge angles implied by the claim
- Timing: argue GT4P was not administered for a time period “sufficient for steady state,” or that the steady-state period did not align with the dependent timing windows in claims 2–6.
- Testing cadence: show multiple fasting draws were used (thus “not serial blood draws” is not met).
- Threshold framing: demonstrate the titration threshold was not “greater than half the upper limit of normal” as defined by the lab reference range.
- Patient selection: show inclusion of subjects with fasting ammonia not less than ULN at baseline, or during crisis, violating claim 1 eligibility.
- Testing regimen: for claim 9, show non-overnight fasting.
Key Takeaways
- US 10,183,003 claim 1 covers a GT4P UCD treatment algorithm: initial oral GT4P, wait for steady state, then perform one fasting venous ammonia measurement and increase the dose if fasting ammonia is >0.5 ULN (ULN tied to the lab reference range).
- Patient selection is narrow: baseline fasting ammonia must be below lab ULN and the patient must be not in hyperammonemic crisis.
- Dependent claims lock in: 48 hours, 48–72 hours, 72 hours–1 week, 1–2 weeks, or >2 weeks steady-state timing; optional repeat titration until ≤0.5 ULN; 35 μmol/L ULN; and overnight fasting.
- The method’s enforcement and design-around focus on protocol details: single vs serial ammonia draws, steady-state timing, lab ULN definition, and dose-adjustment rule.
FAQs
1) What does “not serial blood draws” mean for infringement risk under US 10,183,003?
It limits coverage to methods using one fasting venous ammonia measurement at the steady-state assessment step, not repeated measurements.
2) If a protocol uses half-ULN as a decision point but uses a different reference cutoff than the laboratory ULN, does that avoid claim 1?
Potentially, because claim 1 requires comparing the fasting value to the laboratory’s upper limit of normal for the reference range used by that lab.
3) Does US 10,183,003 cover dose reductions or withholding dose when fasting ammonia is above 0.5 ULN?
The claim language you provided requires dose adjustment greater than initial dosage if fasting ammonia is greater than half the ULN, so protocols that do not increase dose in that scenario do not track the claim’s key step.
4) Which claims are most sensitive to clinical laboratory practices: unit conversions, ULN selection, and fasting duration?
Claim 1 (lab-specific ULN concept), claim 8 (fixed 35 μmol/L), and claim 9 (overnight fasting).
5) Can a titration protocol that measures after steady state multiple times still infringe?
Claim 1’s “single fasting venous blood ammonia level… not serial blood draws” conflicts with serial measurement designs, so infringement risk is reduced for protocols that require multiple fasting venous tests in that steady-state step.
References
No references included because the prompt provided only the claim text for US 10,183,003 and did not include the patent’s specification, prosecution history, assignee, filing/publication data, or other cited documents.
